MB-CART19.1
- Generic Name
- MB-CART19.1
MB-CART19.1 in Refractory SLE
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 29
- Registration Number
- NCT06189157
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Medizinische Klinik 3, Erlangen, Germany
🇩🇪Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany
🇩🇪Universitatsklinikum Tubingen - Medizinische Universitätsklinik Abt. II, Tübingen, Germany
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
Phase 1
Recruiting
- Conditions
- B-cell Lymphoma RecurrentB-cell Lymphoma RefractoryAcute Lymphoblastic Leukemia RecurrentChronic Lymphocytic Leukemia RefractoryChronic Lymphocytic Leukemia Recurrent
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT03853616
- Locations
- 🇩🇪
Charite - Medical Clinic with focus on hematology, oncology and tumor immunology, Berlin, Germany
🇩🇪Charité - University clinic, pediatric clinic with focus on oncology and hematology, Berlin, Germany
🇩🇪University clinic, clinical for children and youth, Erlangen, Germany
MB-CART19.1 in Patients With R/R ALL
Phase 2
- Conditions
- Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory
- Interventions
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- Shanghai Children's Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT03321123
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath